| 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对 具体的持续督导工作制定相应的工作计划 | 保荐机构已建立健全并有效执 行了持续督导制度，并制定了 | | | | 相应的工作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始 议，明确双方在持续督导期间的权利义务，并报 | 保 荐 机 构 已 与 诺 诚健 华 签 订 《保荐协议》及《持续督导协 | | | 前，与上市公司或相关当事人签署持续督导协 | 议》，该协议明确了双方在持 | | | | 续督导期间的权利和义务，并 | | | 上海证券交易所备案 | 报上海证券交易所备案 | | 3 | 持续督导期间，按照有关规定对上市公司违法违 规事项公开发表声明的，应于披露前向上海证券 | 2024年度诺诚健华在持续督导 期间未发生按有关规定需保荐 机构公开发表声明的违法违规 | | | 媒体上公告 | 情况 | | 4 | 违规、违背承诺等事项的，应自发现或应当自发 | 年度诺诚健华在持续督导 2024 期间未发生违法违规或违背承 | | 5 | 通过日常沟 ...

Core Viewpoint - The company, Innovent Biologics, has announced that its oncology pipeline candidates ICP-248, ICP-723, and ICP-B05 will present their latest research findings at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the advancements in their clinical trials and potential therapeutic applications [1][2][3][4]. Group 1: Project Details - **ICP-248 (Mesutoclax)**: A novel oral BCL2 inhibitor aimed at treating non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML). The company will present preliminary safety and efficacy data for this drug at ASCO [2]. - **ICP-723 (Zurletrectinib)**: A second-generation pan-TRK inhibitor designed for patients with advanced or metastatic solid tumors carrying NTRK gene fusions. The company has submitted a new drug application for this candidate in China and will present data on its efficacy and safety in pediatric patients at ASCO [3]. - **ICP-B05 (CM369)**: An anti-CCR8 monoclonal antibody developed in collaboration with Connoa Biopharmaceuticals, targeting regulatory T cells in the tumor microenvironment. The company is conducting Phase I clinical trials and will present initial results at ASCO [4].

| 股代码：688428 A | 股简称：诺诚健华 A | 公告编号：2025-012 | | --- | --- | --- | | 港股代码：09969 | 港股简称：诺诚健华 | | 诺诚健华医药有限公司 自愿披露关于多项肿瘤管线最新研究成果入选 2025 年美国临床肿瘤学会（ASCO）年会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 诺诚健华医药有限公司（以下简称"公司"或"诺诚健华"）肿瘤管线 ICP-248 （Mesutoclax）、ICP-723（Zurletrectinib）和 ICP-B05（CM369）最新研究成果入 选 2025 年美国临床肿瘤学会（ASCO）大会，并将在大会上公布一系列在研管线 最新数据。 2025 年 ASCO 年会将于 2025 年 5 月 30 日到 6 月 3 日在芝加哥举办。ASCO 年会是全球肿瘤领域权威的学术交流盛会，将展示当前国际前沿的临床肿瘤学科 研成果和肿瘤治疗技术。 一、入选项目情况 1 抑制剂治疗，以及对第一代 TRK 抑制剂产生耐药的携带 NTRK ...

Trading Information Summary - As of April 3, 2025, the stock price of Nocera Health (688428) closed at 18.48 CNY, down by 2.69% with a turnover rate of 2.14% and a trading volume of 56,900 shares, amounting to a total transaction value of 106 million CNY [1] - On the same day, the net outflow of main funds was 2.36 million CNY, accounting for 2.22% of the total transaction value; net inflow from retail investors was 1.92 million CNY, representing 1.8% of the total transaction value [1][3] Company Announcements Summary - Nocera Health submitted a securities change monthly report as of March 31, 2025, indicating that the total issued shares remained unchanged, with 1,496,284,235 shares listed on the Hong Kong Stock Exchange and 266,282,967 shares listed on the Shanghai Stock Exchange [1][3] - The company has initiated a stock incentive plan for 2023, granting 7,209,000 shares at a price of 6.95 CNY per share, with 522,500 shares becoming invalid by the end of March 2025. For 2024, 9,870,200 shares were granted at a price of 6.65 CNY per share, with 40,000 shares invalidated by the same date [2]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年4月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 USD | | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 USD | ...

Investment Rating - The investment rating for the company is "Buy" and the rating has been maintained [2][3] Core Insights - The company achieved a revenue of 1.009 billion yuan in 2024, representing a year-on-year growth of 36.68%, with drug sales revenue reaching 1.006 billion yuan, up 49.74% [3] - The net profit attributable to shareholders was a loss of 440 million yuan, narrowing by 30% [3] - The first commercialized product, the BTK inhibitor Obutinib, saw sales exceed 1 billion yuan in 2024, growing by 49.14% year-on-year, driven by multiple factors including its inclusion in the national medical insurance catalog [4] - The company is advancing its self-developed ADC platform, with the first IND submission expected within the year [2][4] Financial Performance and Forecast - Revenue forecasts for 2025, 2026, and 2027 are projected at 1.411 billion yuan, 1.702 billion yuan, and 2.058 billion yuan respectively, with net profits expected to be losses of 427 million yuan, 355 million yuan, and 235 million yuan [9][11] - The company is expected to continue benefiting from the growth of Obutinib and the anticipated approval of Tafasitamab, which is expected to contribute to revenue in 2025 [9][11] Clinical Development - The company has initiated a registration Phase III clinical trial for ICP-248 in combination with Obutinib for the treatment of 1L CLL/SLL, with promising clinical data reported [5] - The company is also exploring multiple indications in the autoimmune field, with ongoing clinical trials for Obutinib in treating PPMS, SPMS, and ITP [6] - The second-generation TRK inhibitor ICP-723 has shown a high overall response rate of 85.5% in clinical trials and is expected to submit an NDA soon [8] Market Position and Future Prospects - The company is positioned to expand its market presence with the anticipated approval of Tafasitamab and the ongoing development of its ADC platform targeting difficult-to-treat solid tumors [4][9] - The strong commercial capabilities and the positive clinical outcomes of its products are expected to drive future growth [4][9]

Investment Rating - The investment rating for the company is "Buy" and the rating has been maintained [2][3]. Core Insights - The company achieved a revenue of 1.009 billion yuan in 2024, representing a year-on-year growth of 36.68%, with drug sales revenue reaching 1.006 billion yuan, up 49.74% [3]. - The net profit attributable to shareholders was a loss of 444 million yuan, narrowing by 30% [3]. - The company’s first commercialized product, the BTK inhibitor Acalabrutinib, saw sales exceed 1 billion yuan in 2024, with a growth rate of 49.14% [4]. - The company is advancing its ADC platform and plans to submit its first IND application within the year [4][8]. Financial Performance - The company forecasts revenues of 1.411 billion yuan, 1.702 billion yuan, and 2.058 billion yuan for 2025, 2026, and 2027 respectively, with net profits expected to be losses of 427 million yuan, 355 million yuan, and 235 million yuan [9][11]. - The company’s R&D expenses for 2024 were 815 million yuan, reflecting a year-on-year increase of 7.57% [3]. Product Pipeline and Clinical Trials - The company is progressing with multiple clinical trials, including a Phase III trial for ICP-248 in combination with Acalabrutinib for 1L CLL/SLL, which has shown promising clinical data [5]. - Tafasitamab is expected to be approved in the first half of 2025, contributing to the company's growth trajectory [4]. - The company is also exploring Acalabrutinib's potential in autoimmune diseases, with several clinical trials underway [6]. Market Position and Future Outlook - The company is well-positioned with its core product Acalabrutinib and the anticipated approval of Tafasitamab, which is expected to enhance its revenue streams [9]. - The ADC platform is expected to target hard-to-treat solid tumors, indicating a strategic expansion into new therapeutic areas [8].

自免管线陆续兑现，挖掘未满足临床需求。奥布替尼治疗PPMS和SPMS的全球IⅡI期临床正在启动，有 望在2025年内实现FPI。同时已实现治疗ITF的POC，计划2025年底前完成Ⅲ期注册临床，并于2026年上 半年递交NDA；SLE适应症IIb期试验已完成患者招募，预计2025年四季度数据读出。另外两款差异化 TYK2抑制剂，ICP-332特应性皮炎Ⅲ期临床已入组超过110例惠者，自激风其/Ⅲ期临床已启动，结节性 择疹全球其期临床计划开展；ICP488正加速推进银屑病Ⅲ期临床，首例患者完成入组。公司持续布局 自身免疫性疾病口服疗法，进一步挖掘未满足临床需求。 持续拓展实体瘤领域，首主开发ADC平台值得期待。第二代泛TRK抑制剂ICP-723针对NTRK融合阳性 晚期实体瘤已完成I期注册临床，计划2025年4月初递交NDA，儿童适应症计划2025年下半年递交 NDA。公司自主研发的ADC平台采用不可逆生物偶联技术、亲水链接子及创新型载荷，具备强大的肿 瘤杀伤效应和充足的安全窗口，首款ADC产品ICP-B794（B7-H3ADC)计划于2025年上半年递交IND申 请。 事件：2025年3月28日，诺诚健华发布 ...

中国经济导报 中国发展网讯 2025中关村论坛年会于3月27日至31日在北京举办。生物医药高科技公司诺 诚健华（上交所代码：688428；香港联交所代码：09969）以"科学驱动创新"为发展理念持续亮相中关 村论坛，通过最新研发成果展现"中国方案"对全球患者可及性的创新突破，高质量发展屡获政府认可， 并携手业界共同为论坛主题"新质生产力与全球科技合作"献计献策。 在本届中关村论坛上，诺诚健华先后获得两项表彰：诺诚健华成为唯一入选北京市人民政府质量管理奖 的生物医药企业；公司自主研发的新型口服高选择性BCL2抑制剂Mesutoclax （ICP-248）成功入选《百 项新技术新产品榜单》。这些认可充分展示诺诚健华在技术创新、推动科技成果转化和经营管理方面的 强大实力。 3月29日，第四届北京市人民政府质量管理奖表彰仪式在2025中关村论坛年会期间召开。诺诚健华凭借 行业领先的经营管理、创新水平以及质量管理体系，荣获北京市人民政府质量管理奖提名奖，成为唯一 入选的生物医药企业。本届奖项评选覆盖全市300余家申报单位，历经初审、现场评审等多个环节，最 终仅有10家企业获奖。 全面展示创新成果并再获认可 新质生产力赋 ...

事件：2024 年公司实现营业收入10.1 亿元，同比增长36.7%；归母净亏损4.4 亿元，同比缩窄30.2%。 奥布替尼收入持续高增，新适应症快速推进：2024 年奥布替尼收入10.0 亿元，同比增长49.1%，主要是 归功于r/r MZL 适应症纳入医保后在2024 年实现快速放量，以及商业化团队能力的不断加强。截至2025 年3 月，在血液瘤领域，奥布替尼有三项适应症贡献收入，一项适应症（1L CLL/SLL）处于NDA 阶 段。在自免领域，ITP、MS、SLE 等适应症已推进至临床2/3 期。新适应症的快速推进将持续为奥布替 尼收入增长注入新活力，支撑公司整体业绩稳步增长。 靶向B7H3 ADC 发布，丰富肿瘤管线布局：根据2024 年报，公司推出高度差异化的ADC 平台，采用自 主研发的连接子-载荷（LP）技术，在提高疗效的同时进一步优化安全性。基于该平台，一款靶向B7H3 的新型ADC（ICP-B794）计划于2025 年上半年递交IND申请。在临床前研究中，ICP-B794在SCLC、 NSCLC 及其他实体瘤的CDX 小鼠模型中展现了强效的抗肿瘤活性。 2025 年重要催化剂：1）奥布替尼1 ...